YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities by Stewart, C Allison, Diao, Lixia, Xi, Yuanxin, Wang, Runsheng, Ramkumar, Kavya, Serrano, Alejandra G, Tanimoto, Azusa, Rodriguez, B Leticia, Morris, Benjamin B, Shen, Li, Zhang, Bingnan, Yang, Yan, Hamad, Samera H, Cardnell, Robert J, Duarte, Jr, Alberto, Sahu, Moushumi, Novegil, Veronica Y, Weissman, Bernard E, Frumovitz, Michael, Kalhor, Neda, Solis Soto, Luisa, da Rocha, Pedro, Vokes, Natalie, Gibbons, Don L, Wang, Jing, Heymach, John V, Glisson, Bonnie, Byers, Lauren Averett, Gay, Carl M

Get full text

Abstract 4525: YAP1 in relapsed pulmonary high-grade neuroendocrine carcinomas (NEC) is associated with CDKN2A loss, intact RB1 , EMT and therapeutic vulnerability to MEK1 and CDK4... by Stewart, C. Allison, Diao, Lixia, Xi, Yuanxin, Wang, Runsheng, Ramkumar, Kavya, Rodriguez, B. Leticia, Morris, Benjamin B., Shen, Li, Zhang, Bingnan, Yang, Yan, Tanimoto, Azusa, Novegil, Veronica Y., Soto, Luisa M. Solis, da Rocha, Pedro F. Simoes, Vokes, Natalie, Gibbons, Don L., Frumovitz, Michael, Fujimoto, Junya, Wang, Jing, Glisson, Bonnie, Byers, Lauren A., Gay, Carl M.

Get full text

Abstract CT218: A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas by Gay, Carl M., Stewart, C. Allison, Frumovitz, Michael, Fujimoto, Junya, xi, Yuann, Wang, Qi, Wang, Runsheng, Novegil, Veronica, Altan, Mehmet, Cascone, Tina, Dasari, Arvind, Elamin, Yasir Y., Fossella, Frank V., Glisson, Bonnie S., Lu, Charles S., Negrao, Marcelo V., Skoulidis, Ferdinandos, Vokes, Natalie, Cardnell, Robert J., Wistuba, Ignacio I., Wang, Jing, Heymach, John V., Byers, Lauren A.

Get full text